Evidence map›Paper›PMID 39958627›Full record

ArticleLiver research (Beijing, China)2022

Effects of intestine-specific deletion of fibroblast growth factor 15 on alcoholic liver disease development in mice.

Bo Kong, Mingxing Huang, Rulaiha E Taylor, Daniel Rizzolo, Katherine D Otersen, Grace L Guo

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver research (Beijing, China), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Cholestasis in Alcohol-Associated Liver Disease.The American journal of pathology · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Bo KongDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Mingxing HuangDepartment of Infectious Diseases, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China.
Rulaiha E TaylorDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Daniel RizzoloDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Katherine D OtersenDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Grace L GuoDepartment of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.

Funding

Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activationR01GM135258 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI GUO, GRACE L · 2020 to 2023
$1.4M
Differential roles of FXR and FGF15 in liver fibrosis developmentR21ES029258 · NIEHS · RUTGERS, THE STATE UNIV OF N.J. · PI GUO, GRACE L · 2018 to 2019
$426k
BLRD VA I01 BX002741NIEHS NIH HHS R21 ES029258NIGMS NIH HHS R01 GM135258
6 · The paper itself

Abstract

Background and aims: Alcoholic liver disease (ALD) is an important and growing cause for the development of chronic liver diseases in the world. Bile acid (BA) levels are increased in patients with ALD and dysregulation of BA homeostasis worsens ALD. BA synthesis is critically regulated by fibroblast growth factor (FGF)15 in mice and FGF19 in humans. FGF15/19 are mainly produced in the ileum and their main function is to suppress BA synthesis in the liver through the activation of fibroblast growth factor receptor 4 (FGFR4) on hepatocytes. The effects of intestine-specific Methods: Enterocyte-specific Results: The Conclusions: FGF15 may prevent hepatic steatosis in the development of ALD in mice, and maintaining FGF19/FGFR4 signaling may be critical in the prevention and/or treatment of ALD in humans in the future.

Indexed as

Alcoholic fatty liver diseaseAlcoholic steatohepatitisBile acid (BA)Farnesoid X receptor (FXR)Fibroblast growth factor 15 (FGF15)

Identifiers

PMID39958627
PMCPMC11791802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.